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ABSTRACT 
 
Lung Malignancies are leading cause for cancer incidence and mortality. They 
show all rising trend in the developed and the developing countries. Lung cancers all seen 
mostly in the males, but due to the changing life style and few other genetic factors it is 
also seen to increase in the females. Generally the older age groups are affected. 
Lung malignancies are divided into NSCLC and SCLC. Further the NSCLC are 
divided into Adenocarcinomas and Squamous Cell Carcinomas. Of late this subtyping 
has become essential for various reasons of which the newer treatment modalities is one 
(targeted therapy). Generally, Lung cancers can be diagnosed by radiological, 
Pathological and on clinical basis. To talk about the pathological methods adopted in the 
diagnosis of lung cancer, firstly cytology i.e. Sputum analysis, Bronchial lavage and 
washings or FNAC biopsies can be opted. Other method used is histopathological 
diagnosi which includes TBLB AND EBUS. Diagnosis on these samples are quite 
difficult may be due to its small size and adequacy problems. For such cases where 
cytology or histopathology (H&E) is not sufficient for the diagnosis, IHC is used. With 
the help of IHC, the poorly differentiated NSCLC can be subtyped. 
Normally, a panel of markers are used which includes (TTF-1, NAPSIN, CK5/6, 
and P63) for adenocarcinoma and Squamous Cell Carcinoma. 
Important inclusion in the new WHO (2015) is the Mutational analysis. Lung 
malignancies have various mutations (Kras, AlK, EGFR). The identifications of these 
mutations help in the newly developing treatment modalities (targeted therapy) 
In our study titled “Histopathological and immunohistochemical analysis of 
NSCLC with special emphasis on EFGR mutational status” 50 cases were selected which 
include NSCLC, Adenocarcinoma and Squamous cell Carcinoma, a panel of 4 markers 
were used (TTF-1, NAPSIN< P63, CK5/6). We ultimately derived 28 Adenocarcinomas 
and 22 Squamous Cell Carcinomas. The intensity and the proportion score for  each were 
also analyzed along with the clinical and radiological features. In all the IHC proved 
adenocarcinomas, EFGR study was conducted on 21 cases and 17 cased showed the 
mutation positivity. 
In conclusion, although it is cumbersome ,a more complete and thorough  
examination and sub typing of poorly differentiated NSCLC’s is possible by combining 
H and E , IHC study and mutation specific IHC marker study in proven adenocarcinoma 
cases of small lung biopsy specimens. 
Key words: Lung Carcinoma, Adenocarcinoma, Squamous cell carcinoma, Non 
small cell lung carcinoma, Epidermal growth factor receptor.  
 
